

## Heparin

S

### Heparin-induced thrombocytopenia: case report

A retrospective, single-center, observational study (conducted between 1 March 2020 and 20 April 2020), included 17 COVID-19 patients treated with extracorporeal membrane oxygenation (ECMO) for COVID-19, described a patient [*age and sex not stated*], who developed heparin-induced thrombocytopenia during treatment with heparin [*route, time to reaction onset and outcome not stated*].

The patient, who had COVID-19 with acute respiratory distress syndrome, was admitted and received ECMO treatment. The patient started receiving anticoagulant treatment with heparin [unfractionated heparin] 400 IE/h [*sic*]. However, the patient developed heparin-induced thrombocytopenia II.

Thus, the patient received argatroban instead of heparin. Subsequently, the patient developed a major endobronchial bleeding and pulmonary artery embolism.

Durak K, et al. Thromboembolic and Bleeding Events in COVID-19 Patients receiving Extracorporeal Membrane Oxygenation. *Thoracic and Cardiovascular Surgeon* 69: 526-536, No. 6, Sep 2021. Available from: URL: <http://www.thieme-connect.com/ejournals/toc/thoracic>

803635466